Goodwill
£m
Software
£m
Development
costs
£m
Patent
rights
£m
Marketing
authorisations
£m
Acquired
intangibles
£m
Total
£m
Cost
At 1 July 2016113.29.210.35.00.8340.2478.7
Additions3.21.20.30.234.239.1
Acquisitions through business combinations9.90.121.331.3
Disposals(0.1)(0.3)(0.4)
Foreign exchange adjustments5.00.30.513.719.5
At 30 June 2017 and 1 July 2017128.112.711.75.31.0409.4568.2
Additions4.21.70.98.715.5
Acquisitions through business combinations102.3(2.1)262.3362.5
Remeasurement(3.1)(3.1)
Disposals(0.2)(0.2)(0.4)
Foreign exchange adjustments(1.1)(0.2)(0.1)(3.3)(4.7)
At 30 June 2018229.316.713.23.90.9674.0938.0
Accumulated Amortisation
At 1 July 20162.55.12.6113.2123.4
Charge for the year0.51.00.540.442.4
Disposals(0.1)(0.1)
Foreign exchange adjustments6.26.2
At 30 June 2017 and 1 July 20172.96.13.1159.8171.9
Charge for the year0.81.20.554.156.6
Acquisitions through business combinations(0.4)(0.4)
Impairment0.10.1
Disposals(0.2)(0.2)(0.4)
Foreign exchange adjustments(0.1)0.50.4
At 30 June 20183.77.13.0214.4228.2
Net book value
At 30 June 2018229.313.06.10.90.9459.6709.8
At 30 June 2017128.19.85.62.21.0249.6396.3
2018
£m
2017
£m
Software assets in the course of construction included above9.4

The asset within patent rights comprises payments to acquire the right to develop and market Trilostane, the active ingredient of Vetoryl Capsules, for animal health applications in the USA and Canada. The carrying value at 30 June 2018 was £0.1 million with a remaining amortisation period of 0.5 years. The rights to Equidone, which was launched in the US during 2011, has a carrying value of £0.3 million with a remaining amortisation period of 3 years. The in-licensed products within Canada acquired in 2016 had a carrying value of £0.3 million and had a remaining amortisation periods of 8.5 years. During the year, £0.9 million was added to patent rights within EU from Le Vet B.V. On acquisition of Le Vet during the year this and previously acquired patent rights from Le Vet were reclassified to acquired intangibles (£1.7 million).

£0.8 million of the marketing authorisations relate to the Vetivex range of products. Ownership of the marketing authorisations rests with the Group in perpetuity. There are not believed to be any legal, regulatory or contractual provisions that limit their useful lives. Vetivex is an established range of products which are relatively simple in nature and there are a limited number of players in the market. Accordingly, the Directors believe that it is appropriate that the marketing authorisations are treated as having indefinite lives for accounting purposes.

Goodwill is allocated across cash generating units that are expected to benefit from that business combination. Key assumptions made in this respect are given in note 14.

During the year, the contingent consideration in relation to development milestones and sales milestones of the acquired intangibles has been remeasured and to the extent possible remeasured against the intangibles.

In accordance with the disclosure requirements of IAS 38 'Intangible Assets', the components of acquired intangibles are summarised below:

Commercial relationships
£m
Pharmacological process
£m
Brand
£m
Capitalised
development
costs
£m
Product
rights
£m
Total
£m
Cost
At 1 July 20161.648.812.493.1184.3340.2
Additions34.234.2
Acquisitions through business combinations0.417.93.021.3
Foreign exchange adjustments0.11.70.53.57.913.7
At 30 June 2017 and 1 July 20171.750.513.3114.5229.4409.4
Additions8.78.7
Acquisitions through business combinations4.92.4255.0262.3
Remeasurement(3.1)(3.1)
Foreign exchange adjustments0.1(0.9)(0.3)(2.2)(3.3)
At 30 June 20186.749.615.4367.3235.0674.0
Accumulated Amortisation
At 1 July 20160.20.80.310.7101.2113.2
Charge for the year0.411.42.09.117.540.4
Foreign exchange adjustments0.65.66.2
At 30 June 2017 and 1 July 20170.612.22.320.4124.3159.8
Charge for the year0.78.02.126.916.454.1
Foreign exchange adjustments0.10.40.5
At 30 June 20181.320.24.447.4141.1214.4
Net book value
At 30 June 20185.429.411.0319.993.9459.6
At 30 June 20171.138.311.094.1105.1249.6

The table below provides further detail on the acquired intangibles and their remaining amortisation period.

Significant assetsDescriptionCarrying value £mSub-Total carrying value £mRemaining amortisation period
Intangible assets arising from the acquisition of DermapetProduct, marketing and distribution rights22.722.77 ½ years
Intangible assets arising from the acquisition of GenetrixProduct, marketing and distribution rights1.41.42 ½ years
Intangible assets arising from the acquisition of EurovetTechnology, product, marketing and distribution rights33.533.54 years
Intangible assets arising from the acquisition of PSPC IncProduct, marketing and distribution rights3.93.96 years
Intangible asset acquired from Pharmaderm Animal HealthMarketing and distribution rights0.70.74 years
HY-50 intangible asset acquired from Bexinc LimitedMarketing and distribution rights1.81.83 ½ years
Intangible assets arising from the acquisition of GeneraProduct, brand, technology, marketing and distribution rights1.14 ½ years
0.47 ½ years
8.012 ½ years
9.5Genera – total
Intangible assets arising from the acquisition of PutneyProduct, brand, technology, pharmacological process, marketing and distribution rights8.28 years
29.78 years
50.310 years
88.2Putney – total
Intangible asset arising from the acquisition of ApexProduct and technology14.515 years
2.412 years
0.23 years
17.1Apex – total
Intangible asset related to Animal EthicsMarketing and distribution rights28.228.210 years
Intangible assets related to a US dental licensing agreementMarketing and distribution rights1.01.09 years
Intangible asset related to BiovetaMarketing and distribution rights2.02.010 years
Intangible asset related to an injectable solution licensing agreementMarketing and distribution rights6.56.510 years
Intangible assets related to RxVetBrand0.20.21 ½ years
Intangible assets arising from the acquisition of ASTProduct, brand, technology,86.29 ½ years
Farma and Le Vetmarketing and distribution rights136.68 ½ years
15.610 years
2.22 ½ years
2.24 ½ years
242.8AST Farma and Le Vet – total
Intangible asset related to PremuneProduct0.10.13 years
459.6